{
  "nodes": [
    {
      "id": "node_001",
      "content": "Chest wall, trachea/carina, mediastinum, or diaphragm; T3 invasion, N0–1; resectable T4 invasion, N0–1\nStage IIIA (T4 [size], N0–1) resectable",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_003"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "x"
      ]
    },
    {
      "id": "node_002",
      "content": "Surgery",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_004",
        "node_005"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "m"
      ]
    },
    {
      "id": "node_003",
      "content": "Systemic therapy or Concurrent chemoradiation",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_013"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "q",
        "n",
        "t"
      ]
    },
    {
      "id": "node_004",
      "content": "Margins negative (R0)",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "s"
      ]
    },
    {
      "id": "node_005",
      "content": "Margins positive",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_008",
        "node_009"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_006",
      "content": "Adjuvant systemic therapy (NSCL-E)",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [
        "node_007"
      ],
      "tree_ids": [
        "NSCL-E"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_007",
      "content": "Surveillance (NSCL-17)",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-17"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_008",
      "content": "R1",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "s"
      ]
    },
    {
      "id": "node_009",
      "content": "R2",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [
        "node_011"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "s"
      ]
    },
    {
      "id": "node_010",
      "content": "Reresection + chemotherapy or Chemoradiation (sequential or concurrent)",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "q",
        "n",
        "t"
      ]
    },
    {
      "id": "node_011",
      "content": "Reresection + chemotherapy or Concurrent chemoradiation",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "q",
        "n",
        "t"
      ]
    },
    {
      "id": "node_012",
      "content": "Surveillance (NSCL-17)",
      "parent_ids": [
        "node_010",
        "node_011"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-17"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "Surgical reevaluation including chest CT ± PET/CT",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_014",
      "content": "Surgery",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_015",
        "node_016"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "m"
      ]
    },
    {
      "id": "node_015",
      "content": "Margins negative (R0)",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [
        "node_017"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "s"
      ]
    },
    {
      "id": "node_016",
      "content": "Margins positive (R1, R2)",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [
        "node_018"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "s"
      ]
    },
    {
      "id": "node_017",
      "content": "Observe or Adjuvant systemic therapy (NSCL-E)",
      "parent_ids": [
        "node_015"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [
        "NSCL-E"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_018",
      "content": "Reresection and/or RT boost",
      "parent_ids": [
        "node_016"
      ],
      "children_ids": [
        "node_019"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_019",
      "content": "Adjuvant systemic therapy (NSCL-E)",
      "parent_ids": [
        "node_018"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [
        "NSCL-E"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_020",
      "content": "Stage IIIA (T4, N0–1) unresectable",
      "parent_ids": [],
      "children_ids": [
        "node_021"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_021",
      "content": "Definitive concurrent chemoradiation (category 1)",
      "parent_ids": [
        "node_020"
      ],
      "children_ids": [
        "node_022"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "n",
        "t"
      ]
    },
    {
      "id": "node_022",
      "content": "Durvalumab (if no EGFR exon 19 deletion or L858R) (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
      "parent_ids": [
        "node_021"
      ],
      "children_ids": [
        "node_023"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "t",
        "v"
      ]
    },
    {
      "id": "node_023",
      "content": "Surveillance (NSCL-17)",
      "parent_ids": [
        "node_022"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-17"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_024",
      "content": "Surveillance (NSCL-17)",
      "parent_ids": [
        "node_017",
        "node_019"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-17"
      ],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-7",
      "to_tree": "NSCL-E",
      "description": "Refers to Adjuvant Systemic Therapy guidelines"
    },
    {
      "from_tree": "NSCL-7",
      "to_tree": "NSCL-17",
      "description": "Refers to Surveillance guidelines"
    },
    {
      "from_tree": "NSCL-7",
      "to_tree": "NSCL-B",
      "description": "Principles of Surgical Therapy"
    },
    {
      "from_tree": "NSCL-7",
      "to_tree": "NSCL-C",
      "description": "Principles of Radiation Therapy"
    },
    {
      "from_tree": "NSCL-7",
      "to_tree": "NSCL-F",
      "description": "Concurrent Chemoradiation Regimens"
    }
  ],
  "footnotes": [
    {
      "label": "m",
      "content": "Principles of Surgical Therapy (NSCL-B)."
    },
    {
      "label": "n",
      "content": "Principles of Radiation Therapy (NSCL-C)."
    },
    {
      "label": "q",
      "content": "Perioperative Systemic Therapy (NSCL-E)."
    },
    {
      "label": "s",
      "content": "R0 = complete resection with negative margins, R1 = microscopic positive margins, R2 = gross unresected tumor remaining."
    },
    {
      "label": "t",
      "content": "Concurrent Chemoradiation Regimens (NSCL-F)."
    },
    {
      "label": "v",
      "content": "For patients who have received sequential chemoradiation, durvalumab can be considered as consolidation immunotherapy or, if EGFR exon 19 deletion or L858R, osimertinib is recommended."
    },
    {
      "label": "x",
      "content": "Resectability should be determined by thoracic surgery evaluation prior to initiation of any therapy."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "NCCN Guidelines Version 3.2025 Non-Small Cell Lung Cancer",
  "tree_id": "NSCL-7",
  "keywords": [
    "osimertinib",
    "durvalumab",
    "EGFR"
  ]
}
